In-Depth Examination Of 4 Analyst Recommendations For AdaptHealth
Portfolio Pulse from Benzinga Insights
AdaptHealth (NASDAQ:AHCO) has received mixed analyst ratings over the past three months, with 2 bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target is now $9.88, down from $14.00, with a high estimate of $13.00 and a low of $6.50. Analysts from UBS, RBC Capital, B of A Securities, and Truist Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AdaptHealth's financials show a market cap below industry benchmarks, a revenue growth of 4.67%, a net margin of -77.8%, an ROE of -23.21%, an ROA of -9.15%, and a debt-to-equity ratio of 1.33.
January 29, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AdaptHealth has received varied analyst ratings and a lowered average price target of $9.88, indicating potential bearish sentiment. Financial indicators show growth but also highlight profitability and efficiency challenges.
The reduction in the average price target and the mixed analyst ratings suggest a bearish outlook for AdaptHealth in the short term. The financial indicators, such as the negative net margin and ROE, as well as the below-average revenue growth, may contribute to a negative perception among investors, potentially impacting the stock price negatively.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100